State Street’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,582
| Closed | -$18.5K | – | 4785 |
|
|
2023
Q1 | $18.5K | Hold |
1,582
| – | – | ﹤0.01% | 4689 |
|
|
2022
Q4 | $24.3K | Hold |
1,582
| – | – | ﹤0.01% | 4700 |
|
|
2022
Q3 | $9K | Hold |
1,582
| – | – | ﹤0.01% | 4895 |
|
|
2022
Q2 | $15K | Hold |
1,582
| – | – | ﹤0.01% | 4902 |
|
|
2022
Q1 | $51K | Hold |
1,582
| – | – | ﹤0.01% | 4788 |
|
|
2021
Q4 | $76K | Hold |
1,582
| – | – | ﹤0.01% | 4633 |
|
|
2021
Q3 | $146K | Hold |
1,582
| – | – | ﹤0.01% | 4459 |
|
|
2021
Q2 | $151K | Buy |
+1,582
| New | +$138K | ﹤0.01% | 4280 |
|
|
2021
Q1 | – | Sell |
-303
| Closed | -$25K | – | 3986 |
|
|
2020
Q4 | $25K | Hold |
303
| – | – | ﹤0.01% | 3861 |
|
|
2020
Q3 | $19K | Hold |
303
| – | – | ﹤0.01% | 3798 |
|
|
2020
Q2 | $27K | Sell |
303
-12,139
| -98% | -$1.28M | ﹤0.01% | 3756 |
|
|
2020
Q1 | $1.39M | Buy |
12,442
+200
| +2% | +$39.4K | ﹤0.01% | 3214 |
|
|
2019
Q4 | $3M | Buy |
12,242
+462
| +4% | +$117K | ﹤0.01% | 3089 |
|
|
2019
Q3 | $4.06M | Sell |
11,780
-20,360
| -63% | -$11.1M | ﹤0.01% | 2886 |
|
|
2019
Q2 | $29.6M | Buy |
32,140
+4,350
| +16% | +$5.35M | ﹤0.01% | 1841 |
|
|
2019
Q1 | $44.3M | Buy |
27,790
+5,331
| +24% | +$9.6M | ﹤0.01% | 1517 |
|
|
2018
Q4 | $42M | Buy |
22,459
+144
| +0.6% | +$313K | ﹤0.01% | 1465 |
|
|
2018
Q3 | $52.6M | Buy |
22,315
+6,779
| +44% | +$21M | ﹤0.01% | 1491 |
|
|
2018
Q2 | $53.5M | Sell |
15,536
-5,300
| -25% | -$16.2M | ﹤0.01% | 1433 |
|
|
2018
Q1 | $59.1M | Buy |
20,836
+398
| +2% | +$1.19M | 0.01% | 1319 |
|
|
2017
Q4 | $52.6M | Buy |
20,438
+2,230
| +12% | +$6.34M | ﹤0.01% | 1399 |
|
|
2017
Q3 | $51.7M | Sell |
18,208
-2,426
| -12% | -$6.39M | ﹤0.01% | 1352 |
|
|
2017
Q2 | $48.8M | Buy |
20,634
+7,094
| +52% | +$14.1M | ﹤0.01% | 1363 |
|
|
2017
Q1 | $34.1M | Sell |
13,540
-220
| -2% | -$633K | ﹤0.01% | 1563 |
|
|
2016
Q4 | $31M | Buy |
13,760
+1,391
| +11% | +$3.31M | ﹤0.01% | 1574 |
|
|
2016
Q3 | $31M | Buy |
12,369
+50
| +0.4% | +$149K | ﹤0.01% | 1486 |
|
|
2016
Q2 | $37.7M | Buy |
12,319
+190
| +2% | +$618K | ﹤0.01% | 1318 |
|
|
2016
Q1 | $38.5M | Buy |
12,129
+1,250
| +11% | +$5.19M | ﹤0.01% | 1295 |
|
|
2015
Q4 | $55.8M | Sell |
10,879
-1,990
| -15% | -$8.7M | 0.01% | 1121 |
|
|
2015
Q3 | $40.9M | Sell |
12,869
-601
| -4% | -$2.33M | ﹤0.01% | 1279 |
|
|
2015
Q2 | $53.9M | Buy |
13,470
+1,746
| +15% | +$6.74M | 0.01% | 1220 |
|
|
2015
Q1 | $46.8M | Buy |
11,724
+1,839
| +19% | +$8.42M | ﹤0.01% | 1276 |
|
|
2014
Q4 | $48.5M | Sell |
9,885
-793
| -7% | -$3.4M | ﹤0.01% | 1244 |
|
|
2014
Q3 | $43.4M | Sell |
10,678
-278
| -3% | -$1.04M | ﹤0.01% | 1251 |
|
|
2014
Q2 | $44.3M | Sell |
10,956
-625
| -5% | -$2.55M | ﹤0.01% | 1294 |
|
|
2014
Q1 | $52.7M | Sell |
11,581
-54
| -0.5% | -$218K | 0.01% | 1172 |
|
|
2013
Q4 | $40.8M | Sell |
11,635
-572
| -5% | -$2.23M | ﹤0.01% | 1320 |
|
|
2013
Q3 | $50.2M | Buy |
12,207
+421
| +4% | +$1.81M | 0.01% | 1161 |
|
|
2013
Q2 | $46.7M | Buy |
+11,786
| New | +$48.5M | 0.01% | 1163 |
|
Other funds holding ACOR
DKCM
State Street's ACOR Position: Q2 2023 in Review
State Street sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 1,582 shares — an estimated $18.5K sold.
State Street first reported a position in ACOR in Q2 2013 and held it in 39 quarters. The position peaked at $59.1M in Q1 2018. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.
- State Street reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
- State Street sold 1,582 Acorda Therapeutics shares in Q2 2023, an estimated $18.5K.
- State Street first reported a position in Acorda Therapeutics in Q2 2013 and held it in 39 quarters.
- State Street's Acorda Therapeutics position peaked at $59.1M in Q1 2018.
- 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.
Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.